Trial · NCT05218408
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
NCT05218408, Phase 1, Phase 2, Withdrawn, Celularity Incorporated
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type. Trials, record NCT05218408. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05218408
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
- NCT number
- NCT05218408
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Celularity Incorporated
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Interventions
- CYNK-001 systemic and Intra cavity administration
- First posted
- 2022-02-01
- Last updated
- 2026-06-08
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase I-Number of patients experience Dose limiting toxicity (DLT) | 42 days | Defined as the maximum dose safely administered intravenously or Intracavitary for the treatment of patients with GBM |
| Primary | To establish maximum tolerated dose (MTD) and a Recommended Phase 2a Dose (RP2D) | 42 days | Defined as the number of patients experience Adverse Events and severity |
| Primary | Phase IIa CYNK-001 efficacy | 6 Months | To evaluate CYNK-001 efficacy post tumor resection and survival within PFS6 Month |
| Secondary | Phase 1-Progression free survival at 6 Months | 6 Months | is defined as the time from the tumor resection to the date of first documented disease progression determined in accordance with RANO (and iRANO) or death due to any reason, whichever occurs first |
| Secondary | Overall survival phase I and IIa | 6,9 and 12 months | is defined as the time from the tumor resection until the date of death at 6,9 and 12 months |
| Other | Progression Free survival Phase I and IIa | 9 and 12 months | is defined as the time from the tumor resection until the date of death 9 and 12 months (PFS9 and PFS12) post tumor resection |
| Other | Median Progression Free Survival (mPFS) post tumor resection | 6, 9,12 , 18 and 24 months | is defined as the median 95% CIs time from the tumor resection until the date of death 9 and 12 months (PFS9 and PFS12) post tumor resection |
| Other | Median Overall Survival (mOS) post tumor resection | 12 and 24 months | is defined as the median as the 95%CI time from the tumor resection until the date of death. |
| Other | Time to Progression (TTP) as measured by RANO | 12 and 24 months | is defined as the time from the tumor resection to the date of first documented disease progression determined in accordance with RANO(iRANO). |
| Other | Overall Response Rate (ORR) pre and post tumor resection as measured by RANO | 12 and 24 months | Defined as the proportion of subjects with best overall response of either complete response (CR) or partial response (PR) |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05218408
GET https://conductscience.org/api/trials/v1/NCT05218408/registered